NanoViricides Inc. (NNVC): Meeta R. Vyas, Chief Financial Officer,N...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: Its_lose_not_loose post# 140786

Saturday, 09/29/2018 11:30:06 AM

Saturday, September 29, 2018 11:30:06 AM

Meeta R. Vyas, Chief Financial Officer,NanoViricides, Inc.

Total Calculated Compensation: $228,564
As of Fiscal Year 2017

https://www.bloomberg.com/research/stocks/people/person.asp?personId=10643431&privcapId=22594191

A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche

Keep Last Read

Replies (1) Next 10 Prev Next

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM

InvestorsHub NewsWire

Only $200 per official company press release!